Overexpression of EZH2 associates with a poor prognosis in chronic lymphocytic leukemia

Blood Cells, Molecules, and Diseases

Volumn 54, Issue 1, 2015, Pages 97-102

  Rabello, Doralina do Amaral ^a   Lucena Araujo, Antonio Roberto ^b   Alves Silva, Juliana Carvalho Rocha ^a   da Eira, Vinícius Burnett Aboud Souza ^a   de Vasconcellos, Maria Catarina Cals ^c   de Oliveira, Fábio Morato ^b   Rego, Eduardo Magalhaes ^b   Saldanha Araujo, Felipe ^a   Pittella Silva, Fábio ^a  

^a UNIVERSITY OF BRASILIA   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c HOSPITAL DE BASE DO DISTRITO FEDERAL   (Brazil)

Author keywords

Chronic lymphocytic leukemia; Cytogenetic; EZH2; Gene expression; Histone methyltransferase

Indexed keywords

PROTEIN KINASE ZAP 70; TRANSCRIPTION FACTOR EZH2; EZH1 PROTEIN, HUMAN; EZH2 PROTEIN, HUMAN; POLYCOMB REPRESSIVE COMPLEX 2;

ADULT; AGED; ARTICLE; B LYMPHOCYTE; CANCER GROWTH; CANCER PROGNOSIS; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; EZH1 GENE; EZH2 GENE; FEMALE; GENE; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; LEUKEMOGENESIS; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; BIOSYNTHESIS; CLINICAL TRIAL; ENZYMOLOGY; GENE EXPRESSION REGULATION; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MIDDLE AGED; PROGNOSIS; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; POLYCOMB REPRESSIVE COMPLEX 2; PROGNOSIS; REAL-TIME POLYMERASE CHAIN REACTION; ZAP-70 PROTEIN-TYROSINE KINASE;

EID: 84927080822     PISSN: 10799796     EISSN: 10960961     Source Type: Journal    
DOI: 10.1016/j.bcmd.2014.07.013     Document Type: Article

References (28)

1. Gribben J.G. How I treat CLL up front. Blood 2009, 115:187-197.
2. Hallek M., Cheson B.D., Catovsky D., Caligaris-Cappio F., Dighiero G., Dohner H., et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008, 111:5446-5456.
3. Orchard J., Ibbotson R., Davis Z., Wiestner A., Rosenwald A., Thomas P., et al. ZAP-70 expression and prognosis in chronic lymphocytic leukaemia. Lancet 2004, 363:105-111.
4. Dighiero G., Hamblin T. Chronic lymphocytic leukaemia. Lancet 2008, 371:1017-1029.
5. Foa R., Del Giudice I., Guarini A., Rossi D., Gaidano G. Clinical implications of the molecular genetics of chronic lymphocytic leukemia. Haematologica 2013, 98:675-685.
6. Varier R.A., Timmers H.T.M. Histone lysine methylation and demethylation pathways in cancer. Biochim. Biophys. Acta Rev. Cancer 2011, 1815:75-89.
7. Kn H., Bassal S., Tikellis C., El-Osta A. Expression analysis of the epigenetic methyltransferases and methyl-CpG binding protein families in the normal B-cell and B-cell chronic lymphocytic leukemia (CLL). Cancer Biol. Ther. 2004, 3:989-994.
8. Ayton P.M., Cleary M.L. Molecular mechanisms of leukemogenesis mediated by MLL fusion proteins. Oncogene 2001, 20:5695-5707.
9. Cao Q., Mani R.-S., Ateeq B., Dhanasekaran Saravana M., Asangani Irfan A., Prensner John R., et al. Coordinated regulation of polycomb group complexes through microRNAs in cancer. Cancer Cell 2011, 20:187-199.
10. Schuettengruber B., Chourrout D., Vervoort M., Leblanc B., Cavalli G. Genome regulation by polycomb and trithorax proteins. Cell 2007, 128:735-745.
11. Schlesinger Y., Straussman R., Keshet I., Farkash S., Hecht M., Zimmerman J., et al. Polycomb-mediated methylation on Lys27 of histone H3 pre-marks genes for de novo methylation in cancer. Nat. Genet. 2006, 39:232-236.
12. Yan J., Ng S.B., Tay J.L.S., Lin B., Koh T.L., Tan J., et al. EZH2 overexpression in natural killer/T-cell lymphoma confers growth advantage independently of histone methyltransferase activity. Blood 2013, 121:4512-4520.
13. Tanaka S., Miyagi S., Sashida G., Chiba T., Yuan J., Mochizuki-Kashio M., et al. Ezh2 augments leukemogenicity by reinforcing differentiation blockage in acute myeloid leukemia. Blood 2012, 120:1107-1117.
14. Jankowska A.M., Makishima H., Tiu R.V., Szpurka H., Huang Y., Traina F., et al. Mutational spectrum analysis of chronic myelomonocytic leukemia includes genes associated with epigenetic regulation: UTX, EZH2, and DNMT3A. Blood 2011, 118:3932-3941.
15. Chen J., Li J., Han Q., Sun Z., Wang J., Wang S., et al. Enhancer of zeste homolog 2 is overexpressed and contributes to epigenetic inactivation of p21 and phosphatase and tensin homolog in B-cell acute lymphoblastic leukemia. Exp. Biol. Med. 2012, 237:1110-1116.
16. Khan S.N., Jankowska A.M., Mahfouz R., Dunbar A.J., Sugimoto Y., Hosono N., et al. Multiple mechanisms deregulate EZH2 and histone H3 lysine 27 epigenetic changes in myeloid malignancies. Leukemia 2013, 27:1301-1309.
17. Matutes E., Owusu-Ankomah K., Morilla R., Garcia Marco J., Houlihan A., Que T.H., et al. The immunological profile of B-cell disorders and proposal of a scoring system for the diagnosis of CLL. Leukemia 1994, 8:1640-1645.
18. Rawstron A.C., Kennedy B., Evans P.A., Davies F.E., Richards S.J., Haynes A.P., et al. Quantitation of minimal disease levels in chronic lymphocytic leukemia using a sensitive flow cytometric assay improves the prediction of outcome and can be used to optimize therapy. Blood 2001, 98:29-35.
19. International Standing Committee on Human Cytogenetic N, Shaffer L.G., Slovak M.L., Campbell L.J. ISCN 2009: An International System for Human Cytogenetic Nomenclature 2009, Karger, Basel; Unionville, CT.
20. Pfaffl M.W. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 2001, 29.
21. Crespo M., Villamor N., Giné E., Muntañola A., Colomer D., Marafioti T., et al. ZAP-70 expression in normal pro/pre B cells, mature B cells, and in B-cell acute lymphoblastic leukemia. Clin. Cancer Res. 2006, 12:726-734.
22. Richardson S.J. ZAP-70 expression is associated with enhanced ability to respond to migratory and survival signals in B-cell chronic lymphocytic leukemia (B-CLL). Blood 2006, 107:3584-3592.
23. Claus R., Lucas D.M., Stilgenbauer S., Ruppert A.S., Yu L., Zucknick M., et al. Quantitative DNA methylation analysis identifies a single CpG dinucleotide important for ZAP-70 expression and predictive of prognosis in chronic lymphocytic leukemia. J. Clin. Oncol. 2012, 30:2483-2491.
24. Chase A., Cross N.C.P. Aberrations of EZH2 in cancer. Clin. Cancer Res. 2011, 17:2613-2618.
25. Margueron R., Li G., Sarma K., Blais A., Zavadil J., Woodcock C.L., et al. Ezh1 and Ezh2 maintain repressive chromatin through different mechanisms. Mol. Cell 2008, 32:503-518.
26. Cao P., Deng Z., Wan M., Huang W., Cramer S.D., Xu J., et al. MicroRNA-101 negatively regulates Ezh2 and its expression is modulated by androgen receptor and HIF-1α/HIF-1β. Mol. Cancer 2010, 9.
27. Papakonstantinou N., Ntoufa S., Chartomatsidou E., Papadopoulos G., Hatzigeorgiou A., Anagnostopoulos A., et al. Differential microRNA profiles and their functional implications in different immunogenetic subsets of chronic lymphocytic leukemia. Mol. Med. 2013, 19:115-123.
28. Sauvageau M., Sauvageau G. Polycomb group proteins: multi-faceted regulators of somatic stem cells and cancer. Cell Stem Cell 2010, 7:299-313.